Bleeding Disorder Testing Market - By Product (Reagent & Consumables, Instruments), By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), By End-use (Hospitals & Clinics, Diagnostic Centers) & Forecast, 2023 – 2032

Bleeding Disorder Testing Market Size

Bleeding Disorder Testing Market size was valued at around USD 88 million in 2022 and is projected to register around 7% CAGR between 2023 and 2032. Increasing prevalence of hemophilia along with other bleeding disorders across the globe will fuel the market growth.
 

The bleeding disorder testing has improved substantially over the recent years, pertaining to the emergence of novel & accurate diagnostics. Also, in order to promote awareness regarding this disorder & associated diagnosis, several federal agencies & public associations are coming forward to increase awareness. Moreover, in recent years, awareness associated with the significance of early-stage diagnosis of bleeding disorders and its potential benefit is rising significantly in the European countries, thereby accelerating the demand for bleeding disorder testing.
 

Bleeding disorder testing involves various laboratory tests & procedures that assists in diagnosing and monitor bleeding disorders. These testing kits and analyzing instruments are extensively used in the diagnosis of bleeding disorders that include hemophilia, von Willebrand disease, idiopathic thrombocytopenic purpura, and platelet function disorders among others. These tests help identify the underlying cause of abnormal bleeding or bruising, evaluate the severity of the disorder, and offer guidance for appropriate treatment.
 

However, the lack of skilled professionals for bleeding disorder testing may adversely affect the market growth. The bleeding disorder testing techniques mandate precise operational skills for accurate diagnosis to assess optimal treatment. Thus, the lack of skilled professionals in emerging economies with poor healthcare infrastructure & medical resources might hamper the disease testing rate, thereby negatively influencing the market revenue growth. As the testing includes various steps such as sample isolation, collection, and analysis that requires precision at every step to avoid false results, it further increases the requirement for a highly educated and knowledgeable workforce. Therefore, limited skilled professionals for bleeding disorder testing might impede the industry growth to a certain extent.
 

Impact of COVID-19 Pandemic

The recent outbreak of COVID-19 has negatively impacted the bleeding disorder testing market revenue growth during the initial quarters of 2020. The lucrative demand for COVID-19 testing had substantially impacted other disease testing services. During the initial period, the incidence, as well as the mortality rate of COVID-19, was highest, and people tended to avoid any other treatment or diagnosis procedures at healthcare facilities. The risk of infection during bleeding disorder testing at diagnostic facilities had resulted in procedure deferral. The disruption in disease testing services, difficulties in product distribution, and supply chain with movement restrictions across borders has further impacted the revenue of several industry players amidst the pandemic in fiscal year 2020. However, the reduced incidence of COVID-19 cases and collaborated efforts undertaken by the major market players & federal agencies to uplift the market growth are set to benefit the industry growth.
 

Bleeding Disorder Testing Market Trends

The increasing prevalence of bleeding disorders is projected to drive the demand for precise & timely diagnostics, thereby propelling the industry growth. The rising cases of bleeding disorders such as hemophilia A, hemophilia B, platelet function disorders, hemorrhagic telangiectasia, etc. is set to drive the market growth significantly. For instance, as per the National Centers for Biotechnology Information (NCBI), in 2022, hemophilia A affects around 1 in 5000 males making it the most common congenital coagulopathy; while hemophilia B is an X-linked genetic coagulopathy affects approximately 1 in 30,000 male births in the U.S. This significant prevalence is expected to have a substantial impact on the market, as the number of dependent patients requiring accurate diagnostics increases.
 

Furthermore, patients that undergo diagnosis & are detected with bleeding disorders in the early stage are likely to develop fewer co-morbid conditions and have a lower risk of severe bleeding. Thus, the ever-increasing patient population has significantly increased demand for precise diagnostics, thereby driving the adoption of bleeding disorder testing.
 

Bleeding Disorder Testing Market Analysis

Based on product, the market is segmented as reagents & consumables and instruments. Reagents & consumables dominated the market in 2022 accounting for more than 58% of the total revenue share. This high revenue share is majorly attributed to the availability of precise diagnostic kits, numerous product launches, and frequent technological advancements in the diagnostic technology. For instance, in March 2020, Siemens Healthineers launched its new Sysmex CS-2500 System with PS-2500 Automated Sample Preparation Module. This modality is a fully automated hemostasis analyzer that provides high throughput testing and improved efficiency. Such product launches offer improved functionality and more reliable diagnostics. Hence, the above-mentioned factors are projected to significantly fuel the bleeding disorder testing market statistics.
 

Based on indication, the bleeding disorder testing market is segmented as hemophilia A, hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, and others. The hemophilia A segment held the largest revenue share in 2022 and is expected to significantly expand at a 7.5% CAGR from 2023-2032. This significant segmental share is due to the higher prevalence of hemophilia A, significant products that cater to the condition, and surging disease awareness among the population.
 

Based on end-use, the bleeding disorder testing market is segmented as hospitals & clinics, diagnostic centers, and others. The diagnostic laboratories segment accounted for over USD 38 million in 2022 and is projected to expand at a notable pace throughout the forecast period. This considerable segment growth is owing to the availability of specialized and efficient diagnoses with rising awareness related to severe bleeding diseases. The expansion of diagnostic laboratory chains with developing infrastructure providing clinical testing services for a wide range of diseases is set to proliferate the market revenue. These diagnostic laboratories are aimed towards the expansion of their reach across the nation to provide diagnostic services including bleeding disorder testing.
 

Additionally, the use of advanced screening mechanisms at diagnostic laboratories drives patient preference. Thus, considering the above-mentioned factors, the increasing testing at diagnostic laboratories will drive the market demand during the estimation timeframe.
 

U.S. dominated the North America bleeding disorder testing market with a dominant revenue share in 2022 and is anticipated to reach more than USD 54 million by 2032. This high revenue surge is majorly attributed to multiple variables such as the facilitative initiatives, high disease prevalence, new product launches along with the presence of established manufacturers. The increasing awareness associated with technologically novel products and the surging target population pool is also contributing to the market revenue growth.
 

Bleeding Disorder Testing Market Share

Some of the major players operating in the bleeding disorder testing industry are

• Siemens Healthineers
• F Hoffmann La Roche AG
• Bio-Rad Laboratories
• Thermo Fischer Scientific Inc
• Cephied (Danaher Corporation)
• Abbott Laboratories Inc.

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers.
 

Bleeding Disorder Testing Industry News:

• In October 2022, Siemens Healthineers announced the introduction of its INNOVANCE VWF Ac assay, a fully automated assay for use on the Siemens Healthineers BCS XP System, as well as on the Sysmex CS-2500 and CS-5100 hemostasis analyzers. The assay's VWF:GPIbM technology allows for a more accurate functional assessment of VWF activity with greater precision and heightened sensitivity, and the ability to detect VWF variants that otherwise might be missed compared to other commercially available VWF assay technologies. This launch helped the company to introduce innovative products, further offering a competitive edge.
   

Bleeding disorder testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD and Units from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product

• Reagents & Consumables
• Instruments

By Indication

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Idiopathic Thrombocytopenic Purpura
• Others

By End-use

• Hospitals and clinics
• Diagnostic Centers
• Others  

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey